07:38 AM EDT, 09/26/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Thursday that the US Food and Drug Administration approved Tagrisso as treatment of adult patients with a specific type of non-small cell lung cancer whose disease has not progressed after platinum-based chemoradiation therapy.

The approval was based on data from a phase 3 trial, which showed that Tagrisso reduced the risk of disease progression or death by 84%, compared with placebo.

Price: 77.72, Change: +0.18, Percent Change: +0.23